Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386317812> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4386317812 abstract "Abstract Background T4b esophageal cancer, chemoradiotherapy with 5FU plus cisplatin (FP-RT) is usually performed as a treatment option. However, its therapeutic efficacy has not been satisfactory, and there is still no certain opinion on its use, including induction therapy and surgical intervention. In recent years, favorable outcomes of radiation therapy with DCF (DCF-RT) have been reported, but there is no consensus. Therefore, we aimed to retrospectively analyze the outcomes of DCF-RT of our hospital. Methods We retrospectively analyzed the safety and efficacy of 61 patients treated with DCF-RT for cT4 esophageal cancer from March 2014 to December 2021. The regimens were (DTX: 30/m2 Day1, CDDP: 10 mg/m2 Day1–5, 5-FU: 400 mg/m2 Day1–5) 2 courses or (DTX: 35/m2 Day1, CDDP: 40 mg/m2 Day1, 5-FU: 400 mg/m2 Day1–5) 3 courses + RT (40-60Gy). Results The main location of tumor was Ce/Ut/Mt/Lt = 20/8/24/2 cases. Dose reduction was required in 19 cases (33%); CTCAE ver 4.0 Grade 3 or higher adverse events were leukopenia 53%, neutropenia 51%, febrile neutropenia 19%, anorexia 12%; no treatment-related deaths were observed. Clinical response was CR/PR/SD/PD = 3/42/9/3 patients, with a response rate of 79%. Clinically downstage from T4 was achieved in 42 patients (74%), and esophagectomy was performed in 51 patients (91%). 20 patients (38%) required combined resection of T4b organs and 48 patients (94%) achieved R0 resection. Pathological response was Grade 1/2/3/NA = 12/24/12/4, and overall survival (1Y/2Y/3Y) = 86/68/54% after CRT. In summary, DCF-RT for T4 esophageal cancer seemed to be relatively safe and may contribute to long survial." @default.
- W4386317812 created "2023-09-01" @default.
- W4386317812 creator A5003369202 @default.
- W4386317812 creator A5020767634 @default.
- W4386317812 creator A5026657616 @default.
- W4386317812 creator A5028284770 @default.
- W4386317812 creator A5043504350 @default.
- W4386317812 creator A5046522921 @default.
- W4386317812 creator A5047261124 @default.
- W4386317812 creator A5070072005 @default.
- W4386317812 creator A5073472318 @default.
- W4386317812 creator A5083681784 @default.
- W4386317812 date "2023-08-30" @default.
- W4386317812 modified "2023-09-27" @default.
- W4386317812 title "178. OUTCOME OF DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL COMBINATION CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL CANCER" @default.
- W4386317812 doi "https://doi.org/10.1093/dote/doad052.044" @default.
- W4386317812 hasPublicationYear "2023" @default.
- W4386317812 type Work @default.
- W4386317812 citedByCount "0" @default.
- W4386317812 crossrefType "journal-article" @default.
- W4386317812 hasAuthorship W4386317812A5003369202 @default.
- W4386317812 hasAuthorship W4386317812A5020767634 @default.
- W4386317812 hasAuthorship W4386317812A5026657616 @default.
- W4386317812 hasAuthorship W4386317812A5028284770 @default.
- W4386317812 hasAuthorship W4386317812A5043504350 @default.
- W4386317812 hasAuthorship W4386317812A5046522921 @default.
- W4386317812 hasAuthorship W4386317812A5047261124 @default.
- W4386317812 hasAuthorship W4386317812A5070072005 @default.
- W4386317812 hasAuthorship W4386317812A5073472318 @default.
- W4386317812 hasAuthorship W4386317812A5083681784 @default.
- W4386317812 hasBestOaLocation W43863178121 @default.
- W4386317812 hasConcept C121608353 @default.
- W4386317812 hasConcept C126322002 @default.
- W4386317812 hasConcept C141071460 @default.
- W4386317812 hasConcept C2776694085 @default.
- W4386317812 hasConcept C2777063308 @default.
- W4386317812 hasConcept C2777297899 @default.
- W4386317812 hasConcept C2778239845 @default.
- W4386317812 hasConcept C2778424827 @default.
- W4386317812 hasConcept C2778850193 @default.
- W4386317812 hasConcept C2779742542 @default.
- W4386317812 hasConcept C2780456651 @default.
- W4386317812 hasConcept C2780873365 @default.
- W4386317812 hasConcept C2781190966 @default.
- W4386317812 hasConcept C509974204 @default.
- W4386317812 hasConcept C71924100 @default.
- W4386317812 hasConcept C90924648 @default.
- W4386317812 hasConceptScore W4386317812C121608353 @default.
- W4386317812 hasConceptScore W4386317812C126322002 @default.
- W4386317812 hasConceptScore W4386317812C141071460 @default.
- W4386317812 hasConceptScore W4386317812C2776694085 @default.
- W4386317812 hasConceptScore W4386317812C2777063308 @default.
- W4386317812 hasConceptScore W4386317812C2777297899 @default.
- W4386317812 hasConceptScore W4386317812C2778239845 @default.
- W4386317812 hasConceptScore W4386317812C2778424827 @default.
- W4386317812 hasConceptScore W4386317812C2778850193 @default.
- W4386317812 hasConceptScore W4386317812C2779742542 @default.
- W4386317812 hasConceptScore W4386317812C2780456651 @default.
- W4386317812 hasConceptScore W4386317812C2780873365 @default.
- W4386317812 hasConceptScore W4386317812C2781190966 @default.
- W4386317812 hasConceptScore W4386317812C509974204 @default.
- W4386317812 hasConceptScore W4386317812C71924100 @default.
- W4386317812 hasConceptScore W4386317812C90924648 @default.
- W4386317812 hasIssue "Supplement_2" @default.
- W4386317812 hasLocation W43863178121 @default.
- W4386317812 hasOpenAccess W4386317812 @default.
- W4386317812 hasPrimaryLocation W43863178121 @default.
- W4386317812 hasRelatedWork W2135790369 @default.
- W4386317812 hasRelatedWork W2347169916 @default.
- W4386317812 hasRelatedWork W2348123719 @default.
- W4386317812 hasRelatedWork W2888298256 @default.
- W4386317812 hasRelatedWork W2907900289 @default.
- W4386317812 hasRelatedWork W3022707871 @default.
- W4386317812 hasRelatedWork W3196402460 @default.
- W4386317812 hasRelatedWork W3201609637 @default.
- W4386317812 hasRelatedWork W3207074224 @default.
- W4386317812 hasRelatedWork W4300863681 @default.
- W4386317812 hasVolume "36" @default.
- W4386317812 isParatext "false" @default.
- W4386317812 isRetracted "false" @default.
- W4386317812 workType "article" @default.